£149.87

Springer Enzyme-Prodrug Strategies for Cancer Therapy

Price data last checked 14 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

This is the most expensive it has ever been. Walk away.

£150 today · previous high £150 · all-time low £149

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 77 days · 77 data points (no recent data)

Historical
Generating forecast…
£149.87 £148.74 £148.98 £149.23 £149.48 £149.73 £149.97 21 May 2026 09 June 2026 28 June 2026 17 July 2026 05 August 2026

Price Distribution

Price distribution over 77 days • 2 price levels

Days at Price
Current Price
25 days 52 days · current 0 13 26 39 52 £149 £150 Days at Price

Price Analysis

Most common price: £150 (52 days, 67.5%)

Price range: £149 - £150

Price levels: 2 different prices over 77 days

Description

Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses the major problem in cancer chemotherapy-its lack of selectivity. Antibody delivery combined with the amplification provided by the enzymatic activation of prodrugs enables selection to be made between tumour and normal tissue. ADEPT offers a novel field of opportunities in the therapy of systemic cancer and may be a major advance for the treatment of solid tumours. This book is the first to describe ADEPT in detail. Each chapter reviews an aspect of the immunology, enzymology, biochemistry, chemistry, and cancer chemotherapy which have been integrated into the ADEPT concept. An additional chapter describes the related approach of gene-directed enzyme prodrug therapy (GDEPT). This latter approach is still in its infancy but ADEPT has entered the clinic. The initial clinical studies with ADEPT are included and discussed in detail.

Product Specifications

Format
paperback
Domain
Amazon UK
Publication Date
06 October 2012
Listed Since
06 December 2012

Barcode

No barcode data available

Similar Products You Might Like

Cellular Therapies for Cancer Treatment: Advancements in Drug Delivery Strategies
83% match

Cellular Therapies for Cancer Treatment: Advancements in Drug Delivery Strategies

Elsevier

£141.99 06 Aug 2026
Gene-Based Therapies for Cancer (Current Cancer Research)
82% match

Gene-Based Therapies for Cancer (Current Cancer Research)

Springer

£108.01 06 Aug 2026
Nutraceuticals and Cancer
82% match

Nutraceuticals and Cancer

Springer

£113.76 05 Aug 2026
Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)
82% match

Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)

Springer

£113.76 06 Aug 2026
Pharmaceutical Perspectives of Cancer Therapeutics
82% match

Pharmaceutical Perspectives of Cancer Therapeutics

Springer

£179.99 08 Aug 2026
Immunotherapy for Gastrointestinal Cancer
81% match

Immunotherapy for Gastrointestinal Cancer

Springer

£99.11 08 Aug 2026
Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins (Milestones in Drug Therapy)
81% match

Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins (Milestones in Drug Therapy)

Springer

£113.77 05 Aug 2026
Cancer Immunotherapy: Paradigms, Practice and Promise
81% match

Cancer Immunotherapy: Paradigms, Practice and Promise

Springer

£108.01 06 Aug 2026
Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models
81% match

Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models

Springer

£74.57 08 Aug 2026
Regulation of Carcinogenesis, Angiogenesis and Metastasis by the Proprotein Convertases (PC's): A New Potential Strategy in Cancer Therapy
81% match

Regulation of Carcinogenesis, Angiogenesis and Metastasis by the Proprotein Convertases (PC's): A New Potential Strategy in Cancer Therapy

Springer

£123.45 10 Aug 2026
Alternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs
81% match

Alternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs

Springer

£77.90 04 Aug 2026
Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances: 42 (Cancer Treatment and Research, 42)
80% match

Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances: 42 (Cancer Treatment and Research, 42)

Springer

£107.85 06 Aug 2026
Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)
80% match

Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)

Springer

£108.01 10 Aug 2026
Cancer Drug Discovery: Science and History
80% match

Cancer Drug Discovery: Science and History

Springer

£113.76 05 Aug 2026
Resistance to Immunotoxins in Cancer Therapy: 6 (Resistance to Targeted Anti-Cancer Therapeutics, 6)
80% match

Resistance to Immunotoxins in Cancer Therapy: 6 (Resistance to Targeted Anti-Cancer Therapeutics, 6)

Springer

£76.42 06 Aug 2026
General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology
80% match

General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology

Springer

£149.86 04 Aug 2026
Drug Targeting Complexity: Tissue-Specific Regulation and Molecular Paradigms in Cancer Therapy
80% match

Drug Targeting Complexity: Tissue-Specific Regulation and Molecular Paradigms in Cancer Therapy

Elsevier

£135.56 05 Aug 2026
Cancer Genetics and Therapeutics: Focus on Phytochemicals
80% match

Cancer Genetics and Therapeutics: Focus on Phytochemicals

Springer

£76.42 05 Aug 2026
Targeted Radionuclide Tumor Therapy: Biological Aspects
80% match

Targeted Radionuclide Tumor Therapy: Biological Aspects

Springer

£139.97 04 Aug 2026
Molecular Basis for Therapy of AIDS-Defining Cancers
80% match

Molecular Basis for Therapy of AIDS-Defining Cancers

Springer

£108.01 05 Aug 2026
Modulation of Protein Stability in Cancer Therapy
80% match

Modulation of Protein Stability in Cancer Therapy

Springer

£73.85 06 Aug 2026
Immunotherapy for Pediatric Malignancies
80% match

Immunotherapy for Pediatric Malignancies

Springer

£113.90 08 Aug 2026
Molecular Oncology: Underlying Mechanisms and Translational Advancements
80% match

Molecular Oncology: Underlying Mechanisms and Translational Advancements

Springer

£80.67 05 Aug 2026
Apoptosis in Carcinogenesis and Chemotherapy: Apoptosis in cancer
80% match

Apoptosis in Carcinogenesis and Chemotherapy: Apoptosis in cancer

Springer

£148.77 04 Aug 2026